Efficient distribution, dissipating stigma and an emphasis on decentralized trials are all working in favor of digital treatments, according to a panel of digital therapeutics executives and industry stakeholders.
The increased adoption of virtual care technologies during the COVID-19 public health emergency is fairly well documented by this point, but a widespread embrace of health technologies is providing a similar upswell on individual niches within the digital health landscape.
One such group of beneficiaries are the companies working to develop, validate and distribute digital therapeutics. Speaking in a virtual panel at the DTx East 2020 web conference, digital therapeutics executives and other industry stakeholders reaffirmed the increased demand for efficient and scalable treatments as providers find their services stretched thin, and patients find themselves cut off from in-person care.
- DrDoctor raises £3m to expand digital patient services platform
- Tech startups developing rapid COVID-19 tests to be taken completely at home
- Possible Discrimination Against Remote Workforce
- Virtualization Efforts in Healthcare Support a Massive Remote Workforce
- New Healthcare Workforce Complexities Require Smarter Solutions